Skip to content
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
Language
Korean
English
Language
Korean
English
Menu
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
Menu
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
Language
Korean
English
Language
Korean
English
Menu
Language
Korean
English
Language
Korean
English
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits
[동문이야기] 만나고 싶었습니다 – 조성진 큐어버스 대표
연세미디어 [전문보기]
관련뉴스 모두보기
난치성 뇌질환 치료약물 개발 기술
Prev
Previous
KIST 개발 ‘먹는 알츠하이머 신약 후보’ 5000억원에 수출 계약
Next
KIST·안젤리니파마·큐어버스 뇌질환 치료제 개발 나선다
Next
About Us
CEO Message
Cureverse
Leadership
Company History
Awards
Contact
R&D
Core Technology
Research Area
Partner Institutions
Publications / National Research Projects
Pipeline
Overview
CV-01
CV-02
CV-03
CV-04
Investor
Media
Investors
Career
Company Culture
Benefits